Treatment of cancers
Case reference FOI2026/01533
Received 5 May 2026
Published 8 May 2026
Request
Response
The most recent data held is for February 2026. In all cases, I’ve therefore provided data from 01/12/2025 – 28/02/2026
REQUEST: Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the
3 months between the start of January 2026 and the end of March 2026, or latest 3-month period available?
Name of medicine Number patients treated
1.1 Abemaciclib (Verzenios) 115 patients
1.2 Alpelisib (Piqray) 0 patients
1.3 Elacestrant (Orserdu) 7 patients
1.4 Fulvestrant (fulvestrant or Faslodex) 40 patients
1.5 Inavolisib (Inaqovi) <5 patients
1.6 Palbociclib (Ibrance) 29 patients
1.7 Ribociclib (Kisqali) 69 patients
1.8 Capivasertib (Truqap) 0 patients
1.9 Talazoparib (Talzenna) 0 patients
1.10 Olaparib (Lynparza) 23 patients
Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period for which data are available? We are unable to specify stage of cancer, so I’ve shown patients with ANY breast cancer diagnosis (ICD10 code beginning C50)
Name of combination or monotherapy Number patients treated
2.1 Abemaciclib (Verzenios) 114 patients
2.2 Ribociclib (Kisqali) 67 patients
2.3 Olaparib (Lynparza) <5 patients
Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period for which data are available? This field is not filled in for all patients, so the below is likely an undercount.
Name of combination or monotherapy Number patients treated
3.1 Abemaciclib (Verzenios) 74 patients
3.2 Ribociclib (Kisqali) 16 patients
Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period available?
Name of combination or monotherapy Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) 0 patients
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) 0 patients
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex) <5 patients
4.4 Inavolisib (Inaqovi) + Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) 0 patients
Q5. How many patients were treated specifically for breast cancer in the 3 months between the start of January 2026 and the end of March 2026?
Type of breast cancer Number patients treated
5.1 Olaparib - All types of breast cancer <5 patients
5.2 Olaparib - Locally advanced or metastatic breast cancer We are unable to specify stage of cancer so cannot answer this question.
5.3 Talazoparib – All types of breast cancer 0 patients
Documents
This is Oxford University Hospitals NHS Foundation Trust's response to a freedom of information (FOI) or environmental information regulations (EIR) request.
You can browse our other responses or make a new FOI request.